ArticleChemSusChem2026
Redefining Fluoroquinolone Antibiotics: Design and Synthesis of Degradable Fluoroquinolones to Reduce Environmental Persistence.
Article in ChemSusChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A significant challenge associated with antibiotics, and active pharmaceutical ingredients in general, is their intentional design for high stability, which promotes environmental persistence and contributes to the development of antibiotic resistance. Ciprofloxacin, a widely used fluoroquinolone antibiotic, exemplifies this issue. Using the benign by design (BbD) approach, ciprofloxacin was redesigned into an environmentally improved fluoroquinolone molecule, termed Cip-hemi. In this design, ciprofloxacin was modified by replacing the persistent cyclopropyl group at the N1 position with a tetrahydrofuran moiety, thereby creating a degradable linker. Herein, we report the development of an efficient and robust synthetic platform to access the Cip-hemi scaffold, along with the preparation of a series of novel derivatives. These molecules are developed with a dual-purpose design: to restore high-level antibacterial action while ensuring rapid degradation in the aquatic environment. The optimized synthetic strategy minimizes the use of hazardous solvents and largely avoids labor-intensive purification by flash chromatography, providing a streamlined approach for the preparation of environmentally improved fluoroquinolones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.